Company intelligence / Profile preview

Refractec

Irvine, California, USA

Ownership: Private
Development stage: Other

Overview

Refractec was a medical device company that pioneered Conductive Keratoplasty (CK), a non-laser refractive surgery used to treat presbyopia and hyperopia. The company's ViewPoint CK system employed radiofrequency energy to shrink corneal collagen, thereby steepening the cornea and improving near vision for patients. FDA-approved in 2002 for hyperopia and in 2004 for presbyopia, the technology was marketed as a safe, "no-cut" alternative to LASIK. Despite its innovative approach to the "aging eye" market, Refractec faced commercial challenges and its assets were eventually acquired by Tracey Technologies in 2011.

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on Refractec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Refractec.

Explore the full profile